Creative Biolabs has a highly experienced team of scientists who have a long history of successfully implementing complex in vitro suppression/stimulation assays. We offer accurate and effective solutions for in vitro suppression/stimulation assays to facilitate our clients' research and project development.
Checkpoint Proteins: Important Target for Immunotherapy
Tumor-specific T cells may be inactivated by immunosuppressive factors in the local tumor microenvironment, such as T-regulatory (Tregs) and myeloid-derived suppressor cells, or by co-inhibitory molecules that modulate T cell activation. In the tumor microenvironment, an increasing number of checkpoint proteins, including lymphocyte activations gene 3 (LAG-3), cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death (PD-1), and B and T lymphocyte attenuator (BTLA), have shown the ability to inhibit anti-tumor T cell responses. When tumor-specific T cells express these checkpoint proteins, they represent a significant barrier for the induction of effective anti-tumor immune responses. Restoring the capacity of T cells to recognize and eliminate tumors is the goal of immunotherapy. Blockade of these receptors has been shown to improve anti-tumor immune T cell responses. For instance, checkpoint blockade has been validated in humans with the approval of the anti-CTLA-4 antibody for metastatic melanoma.
Learn more: Immune Checkpoint In Vitro Stimulation Assay
